Publication Name	World Journal of Diabetes
Manuscript ID	7974
Country	United States

Received	2013-12-10 18:23
Peer-Review Started	2013-12-11 09:50
To Make the First Decision	2014-01-16 08:14
Return for Revision	2014-01-17 13:10
Revised	2014-01-24 23:34
Second Decision	2014-04-03 10:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-03 10:59
Articles in Press	2014-05-23 09:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-13 21:00
Publish the Manuscript Online	2014-06-16 15:44

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Review
Article Title	Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient
Manuscript Source	Invited Manuscript
All Author List	Charmaine D Rochester and Oluwaranti Akiyode
Funding Agency and Grant Number
Corresponding Author	Charmaine D Rochester, PharmD, CDE, BCPS, BCACP, Associate Professor, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201, United States. crochest@rx.umaryland.edu
Key Words	type 2 diabetes mellitus; Sodium dependent glucose co-transporter 2 inhibitors; 11b-Hydroxysteroid dehydrogenase type 1 inhibitors; Glycogen phosphorylase inhibitors; Protein tyrosine phosphatase 1B inhibitors; G protein-coupled receptor agonists; Glucokinase activators
Core Tip	Type 2 diabetes mellitus is a metabolic disorder of deranged fat, protein and carbohydrate metabolism resulting in hyperglycemia. Limited efficacy, adverse effects, cost, contraindications, renal dosage adjustments, inflexible dosing schedules and weight gain significantly limit the use of currently available anti-hyperglycemic agents. In the past, drug researchers targeted defects of pancreatic b-cell failure and insulin resistance, but more recent attention has shifted to other contributing factors. This article reviews new and emerging diabetes classes, including the sodium-glucose cotransporter-2 inhibitors, 11b-Hydroxysteroid dehydrogenase type 1 inhibitors, glycogen phosphorylase inhibitors, protein tyrosine phosphatase 1B inhibitors, G protein-coupled receptor agonists, and glucokinase activators.
Publish Date	2014-06-16 15:44
Citation	Rochester CD, Akiyode O. Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient. World J Diabetes 2014; 5(3): 305-315
URL	http://www.wjgnet.com/1948-9358/full/v5/i3/305.htm
DOI	http://dx.doi.org/10.4239/wjd.v5.i3.305

Full Article (PDF)	WJD-5-305.pdf
Full Article (Word)	WJD-5-305.doc
Manuscript File	7974-Review.docx
Answering Reviewers	7974-Answering reviewers.pdf
Copyright License Agreement	7974-Copyright assignment.pdf
Peer-review Report	7974-Peer review(s).pdf
Scientific Editor Work List	7974-Scientific editor work list.doc